Form 13F-HR JOHNSON & JOHNSON For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
May 9, 2022 5:11 PM EDT
The Securities and Exchange Commission has not necessarily reviewed
the information in this filing and has not determined if it is
accurate and complete.
The reader should not assume that the information is accurate
and complete.
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F COVER PAGE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
July 31, 2015 |
| Estimated average burden |
| hours per response: |
23.8 |
|
|
| Report for the Calendar Year or Quarter Ended: |
03-31-2022 |
| Check here if Amendment |
|
Amendment Number: |
|
| This Amendment (Check only one.): |
|
is a restatement. |
|
|
adds new holdings entries. |
| Institutional Investment Manager Filing
this Report: |
| Name: |
JOHNSON & JOHNSON |
| Address: |
ONE JOHNSON & JOHNSON PLZ |
|
|
|
NEW BRUNSWICK
,
NJ08933
|
| Form 13F File Number: |
028-20072 |
The institutional investment manager filing this report and
the person by whom it is signed hereby represent that the person
signing the report is authorized to submit it, that all information
contained herein is true, correct and complete, and that it is
understood that all required items, statements, schedules, lists, and
tables, are considered integral parts of this form.
| Person Signing this Report on Behalf of
Reporting Manager: |
| Name: |
Matthew Orlando |
| Title: |
Secretary |
| Phone: |
732-524-2455 |
| Signature, Place, and Date of Signing: |
| /s/ Matthew Orlando |
New Brunswick
,
NJ
|
05-09-2022 |
| [Signature] |
[City, State] |
[Date] |
|
| Report Type (Check only one.): |
| X |
13F HOLDINGS REPORT. (Check here if all holdings of
this reporting manager are reported in this report.) |
|
|
13F NOTICE. (Check here if no holdings reported are in
this report, and all holdings are reported by other reporting
manager(s).) |
|
|
13F COMBINATION REPORT. (Check here if a portion of
the holdings for this reporting manager are reported in this
report and a portion are reported by other reporting manager(s).) |
| Form 13F Summary Page |
|
Report Summary: |
|
Number of Other Included
Managers: |
2 |
|
|
|
Form 13F Information Table Entry Total: |
22 |
|
Form 13F Information Table Value Total: |
528,967 |
|
(thousands) |
|
List of Other Managers Reporting for this Manager:
[If there are no entries in this list, omit this section.]
|
|
|
Form 13F File Number |
Name |
|
028-20073 |
Johnson & Johnson Innovation - JJDC, Inc. |
|
028-21422 |
Johnson & Johnson UK Treasury Co Ltd |
| List of Other Included
Managers: |
|
Provide a numbered list of the name(s) and Form 13F file number(s)
of all institutional investment managers with respect to which this
report is filed, other than the
manager filing this report.
|
|
[If there are no entries in this list, state “NONE” and omit the
column headings and list entries.]
|
|
No. |
Form 13F File Number |
Name |
|
1 |
028-20073 |
Johnson & Johnson Innovation - JJDC, Inc. |
|
2 |
028-21422 |
Johnson & Johnson UK Treasury Co Ltd |
The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
The reader should not assume that the information is
accurate and complete.
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F INFORMATION TABLE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
July 31, 2015 |
| Estimated average
burden |
| hours per response:
|
23.8 |
|
|
| COLUMN 1 |
COLUMN 2 |
COLUMN 3 |
COLUMN 4 |
COLUMN 5 |
COLUMN 6 |
COLUMN 7 |
COLUMN 8 |
|
|
|
VALUE |
SHRS OR |
SH/ |
PUT/ |
INVESTMENT |
OTHER |
VOTING AUTHORITY |
| NAME OF ISSUER |
TITLE OF CLASS |
CUSIP |
(x$1000) |
PRN AMT |
PRN |
CALL |
DISCRETION |
MANAGER |
SOLE |
SHARED |
NONE |
| Adicet Bio, Inc. |
COM |
007002108 |
14,557 |
728,944 |
SH |
|
DFND |
1 |
0 |
728,944 |
0 |
| Aldeyra Therapeutics, Inc. |
COM |
01438T106 |
1,755 |
394,834 |
SH |
|
DFND |
1 |
0 |
394,834 |
0 |
| Arrowhead Pharmaceuticals, Inc. |
COM |
04280A100 |
57,987 |
1,260,869 |
SH |
|
DFND |
1 |
0 |
1,260,869 |
0 |
| BiomX Inc. |
COM |
09090D103 |
4,117 |
2,133,402 |
SH |
|
DFND |
1 |
0 |
2,133,402 |
0 |
| Catalyst Biosciences, Inc. |
COM |
14888D208 |
44 |
66,951 |
SH |
|
DFND |
1 |
0 |
66,951 |
0 |
| Cue Health, Inc. |
COM |
229790100 |
35,790 |
5,548,864 |
SH |
|
DFND |
1 |
0 |
5,548,864 |
0 |
| CVRx, Inc. |
COM |
126638105 |
20,938 |
3,495,575 |
SH |
|
DFND |
1 |
0 |
3,495,575 |
0 |
| Fate Therapeutics, Inc. |
COM |
31189P102 |
131,006 |
3,379,064 |
SH |
|
DFND |
1 |
0 |
3,379,064 |
0 |
| Fusion Pharmaceuticals Inc. |
COM |
36118A100 |
28,520 |
3,670,516 |
SH |
|
DFND |
1 |
0 |
3,670,516 |
0 |
| Graybug Vision, Inc. |
COM |
38942Q103 |
61 |
49,547 |
SH |
|
DFND |
1 |
0 |
49,547 |
0 |
| Legend Biotech Corporation |
ADS |
52490G102 |
59,204 |
1,629,173 |
SH |
|
DFND |
1 |
0 |
1,629,173 |
0 |
| MeiraGTx Holdings plc |
COM |
G59665102 |
40,145 |
2,898,550 |
SH |
|
DFND |
1 |
0 |
2,898,550 |
0 |
| Nano-X Imaging Ltd. |
ORD SHS |
M70700105 |
2,086 |
192,429 |
SH |
|
DFND |
1 |
0 |
192,429 |
0 |
| PhaseBio Pharmaceuticals, Inc. |
COM |
717224109 |
2,121 |
1,607,044 |
SH |
|
DFND |
1 |
0 |
1,607,044 |
0 |
| Point Biopharma Global Inc. |
COM |
730541109 |
7,970 |
1,000,000 |
SH |
|
DFND |
1 |
0 |
1,000,000 |
0 |
| Procept BioRobotics Corporation |
COM |
74276L105 |
35,637 |
1,018,478 |
SH |
|
DFND |
1 |
0 |
1,018,478 |
0 |
| Protagonist Therapeutics Inc. |
COM |
74366E102 |
57,997 |
2,449,183 |
SH |
|
DFND |
1 |
0 |
2,449,183 |
0 |
| Senseonics Holdings, Inc. |
COM |
81727U105 |
108 |
54,621 |
SH |
|
DFND |
1 |
0 |
54,621 |
0 |
| Tracon Pharmaceuticals, Inc. |
COM |
89237H209 |
221 |
84,003 |
SH |
|
DFND |
1 |
0 |
84,003 |
0 |
| Vor Biopharma, Inc. |
COM |
929033108 |
6,491 |
1,074,658 |
SH |
|
DFND |
1 |
0 |
1,074,658 |
0 |
| Xencor, Inc. |
COM |
98401F105 |
19,958 |
748,062 |
SH |
|
DFND |
1 |
0 |
748,062 |
0 |
| SomaLogic, Inc. |
COM |
83444K105 |
2,254 |
281,052 |
SH |
|
DFND |
N/A |
0 |
281,052 |
0 |
Tweet
Share
E-mail
